A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
Phase 4
30,000
about 1.6 years
50–64
150 sites in AL, AZ, CA +35
What this study is about
Researchers are testing a treatment, mRNA-1273 and mRNA-1283, in adults aged 50 to 64 who do not have high risk factors for severe COVID-19. The trial will last about 567 days and aims to see if the treatments are effective and safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Placebo
- 2.Receive mRNA-1273
- 3.Receive mRNA-1283
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation, Number of Participants with Unsolicited Adverse Events (AEs)
Infectious